GMO’s Nebo Surpasses $1Billion in Platform Assets One Year After Launch

The Future of Financial Advising is Aligning the Plan with the Portfolio

Grantham, Mayo, Van Otterloo & Co. LLC (GMO), a global investment manager, announced today a major milestone for its Portfolio Design platform Nebo, which has surpassed $1 billion in platform assets1 one year since its September 2022 launch.

Nebo (for Needs-Based Optimization) is a continuation of GMO’s history of research and innovation in areas including asset allocation, quality investing, and quantitative strategies.

Nebo is not just a portfolio construction engine, it is a paradigm shift in risk assessment, redefining risk as ‘not having what you need, when you need it.' Nebo uses a proprietary multi-period shortfall optimization – built on a decade of deep research and user-led development – to generate personalized client portfolios that seek to minimize shortfall risk and align to each client's financial plan.

“We polled more than 400 advisors: do you observe a gap between financial planning and asset management? A resounding 89% said yes, telling us advisors lack confidence that their clients are in the right portfolios. Nebo’s definition of risk is the key to bridging this gap.” said Martin Tarlie, member of GMO’s Asset Allocation team and Nebo Product Lead.

Hyper-personalized, Model Building Capabilities that Eliminate Spreadsheets

Advisors are using Nebo to construct institutional quality, dynamic, real-time model portfolios that are personalized to each client, in a fraction of the time previously required.

“I wanted to find a more robust, systematic way of thinking that could replace my spreadsheets. Nebo has done that,” said Christopher Meyer, Principal, Meritor Capital.2

Nebo is integrated with several leading rebalancers, whereby target portfolios are exported into their multi-level model structure. This allows Nebo to (i) generate custom portfolios for each client with the click of a button, and (ii) send them directly into the rebalancer for trading.

These integrations are helping Heximer Investment Management realize their vision of creating a next-generation, wealth-management practice.   

“Nebo is revolutionary for private wealth management, along the lines of Direct Indexing from a personalization perspective,” said Brandon Kramer, Portfolio Manager at Heximer Investment Management.3

GMO's Nebo platform won “Industry Disruptor” at the September 2022 WealthManagement.com Industry Awards, and is a 2023 finalist in the “Goals-Based Investing Platforms” category. Nebo is also a finalist at the 2023 US FinTech Awards for “WealthTech of the Year."

For RIAs who would like to learn more about Nebo’s capabilities, please visit www.nebo-gmo.com.

About GMO

GMO is a global investment manager that brings together focused expertise within our investment teams, industry-leading research and client solutions and service to advance our clients’ goals. Privately owned and renowned for our conviction in a valuation-based, long-term investment philosophy, GMO has been a partner to institutions, family offices, wealth managers and consultants for over 40 years.


Media:
Tucker Hewes
Hewes Communications, Inc.
212-207-9451
tucker@hewescomm.com

1 Platform assets are defined as all assets on the Nebo platform whether these are assets for which we provide advisory services, referred to as assets under management, or non-advisory assets under administration, assets held in cash accounts or assets otherwise not managed.
2, 3 The above endorsement is from a registered investment adviser (“RIA”) that is not a current advisory client of or investor in any private fund sponsored by GMO, but is a contracted user of the NEBO platform and uses the platform to make allocation decisions for its underlying clients. Although the RIA may from time to time allocate client capital to GMO-managed funds, the RIA has not been compensated directly or indirectly by GMO to provide the statements made herein. The RIA’s experience may not be representative of clients’ or other users’ experiences with GMO or Nebo, which may differ.